|Day Low/High||7.50 / 8.20|
|52 Wk Low/High||3.32 / 17.35|
Presentation Scheduled for Thursday, January 12, 2017 at 10:30am PST
Phase 2 trial of TGR-1202 plus ibrutinib designed to target B-cell receptor (BCR) pathway at multiple points in DLBCL patients relapsed from or ineligible for stem cell transplant
Investors in TG Therapeutics Inc saw new options begin trading this week, for the August 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Combination treatment resulted in 95% ORR in patients with High-Risk CLL, the patient population being evaluated in the Phase 3 GENUINE Trial
Top-line data expected first half 2017
Preclinical work may offer rationale for the differentiated activity and safety effects of TGR-1202
Investor Reception to be Held on Monday December 5, 2016 at 8:00pm PT at the Marriott Gaslamp Hotel with Presentations by Leading Clinical Investigators
Investors in TG Therapeutics Inc saw new options become available this week, for the January 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TGTX options chain for the new January 2017 contracts and identified one put and one call contract of particular interest.
No safety concerns identified; UNITY-CLL Phase 3 trial to continue as planned
Investor Conference Call to be Held Today, Monday, November 7, 2016 at 8:30am ET
Investor Conference Call to be held Monday, November 7, 2016 at 8:30am ET
Investor Reception to be Held on Monday, December 5, 2016 at 8:00pm PT at the Marriott Gaslamp Hotel with Presentations by Leading Clinical Investigators
Investors in TG Therapeutics Inc saw new options begin trading this week, for the December 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TGTX options chain for the new December 16th contracts and identified one put and one call contract of particular interest.
Lundin Law PC ( http://lundinlawpc.com/) announces that it is investigating claims against TG Therapeutics, Inc.
Goldberg Law PC announces that it is investigating TG Therapeutics, Inc.
Levi & Korsinsky, LLP announces that it has commenced an investigation of TG Therapeutics, Inc.
TG Therapeutics (TGTX) filed to adjust protocol for its GENUINE clinical study of a drug combination for leukemia.
Are the Baker Brothers selling Seattle Genetics? Biomarin CEO throws shade on Sarepta. TG Therapeutics management adds to its credibility problem.
Investor Conference Call to be held tomorrow, Thursday, October 13, 2016 at 8:30am ET
Investors eyeing a purchase of TG Therapeutics Inc stock, but tentative about paying the going market price of $7.79/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2017 put at the $7.50 strike, which has a bid at the time of this writing of $1.40.
Presentation Scheduled for Tuesday September 27, 2016 at 11:30am ET
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.